Contracts › 75A50123C00060
75A50123C00060: The Development of a Multimodal Antibody Platform to Extend the Window of Immunotherapeutic Intervention. the Overall Objective of the Work Outlined in This Contract Is to Critically Evaluate the Utility of the Vhh As a Platform Mcm Technology for Vi
Awarded to Eitr Biologics, Inc. by Office of Assistant Secretary for Preparedness and Response.
$33.1Mobligated
$317.6Mpotential value
30 September 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50123C00060 |
|---|---|
| Awardee | Eitr Biologics, Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | 3650 Chemical and Pharmaceutical Products Manufacturing Machinery |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 22 September 2023 to 30 September 2027 |
| Potential end | 30 September 2034 |
| Estimated recompete solicitation | ~Q2 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record